 Immunologic Factors
"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 1 | 3 | | 2006 | 4 | 0 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 1 | 4 | | 2009 | 8 | 4 | 12 | | 2010 | 3 | 3 | 6 | | 2011 | 5 | 4 | 9 | | 2012 | 4 | 1 | 5 | | 2013 | 9 | 1 | 10 | | 2014 | 6 | 3 | 9 | | 2015 | 6 | 0 | 6 | | 2016 | 6 | 6 | 12 | | 2017 | 6 | 3 | 9 | | 2018 | 9 | 0 | 9 | | 2019 | 8 | 2 | 10 | | 2020 | 9 | 9 | 18 | | 2021 | 4 | 4 | 8 | | 2022 | 2 | 11 | 13 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 5 | 6 | | 2025 | 8 | 0 | 8 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Tallantyre EC, Planchon SM, Howard H, Mays J, Frowd N, Cohen JA, Coles A, Hersh CM, Miller DM, Dever M, Gray EH, LaRocca NG, Nakamura K, Bale C, Covey-Crump G, Alvarez E, Arun T, Brownlee WJ, Craner M, Freeman L, Frost N, Goldman MD, Gupta RK, Harding KE, Hobart J, Hutton GJ, Hyland MH, Kalra S, Kannan M, Kantarci O, Lashley D, Lily O, Mahad D, Nicholas JA, Nicholas R, Paling D, Pearson OR, Rice CM, Samudralwar R, Schmalstieg WF, Singh M, Zune The E, Weinstock-Guttman B, Zabeti A, Love TE, Gunzler DD, Liu Y, Gerry S, Evangelou N, Ontaneda D. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 Jun; 32(7):722-736.
-
Vasilenko N, Ruschil C, Stadelmaier J, Tieck MP, Schembecker S, Owens GP, Bennett JL, Berthele A, Ziemann U, Poli S, Snaidero N, Nahnsen S, Jarboui MA, Bichmann L, Gabernet G, Kowarik MC. Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs. J Neuroinflammation. 2026 Apr 14; 23(1).
-
Abrams AW, Waltz M, Casper TC, Aaen G, Benson LA, Bernfeld EM, Charvet LE, Chitnis T, Francisco C, Gorman MP, Graves JS, Krupp L, O'Neill K, Lotze TE, Mar S, Ness J, Rensel M, Rodriguez M, Rose J, Rutatangwa A, Schreiner T, Shukla N, Tillema JM, Weinstock-Guttman B, Wheeler Y, Waubant E, Krysko KM. Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2026 03; 99(3):715-729.
-
Hua LH, Brown B, Camacho E, Chinea AR, Greenberg BM, Henry RG, Houtsma E, Moreo N, Alvarez E. Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study. J Neurol. 2025 Oct 24; 272(11):725.
-
Wright MA, Barney BJ, Peterson S, Waltz M, Rose J, Rensel M, Abrams A, Waubant E, Wheeler Y, Rodriguez M, Tillema JM, Krupp L, Gorman M, Benson L, Lotze T, Shukla N, Mar S, Chitnis T, Schreiner T, Vignos M, Casper TC. Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 Apr; 41(4):545-555.
-
Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep; 12(5):e200450.
-
Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, Palace J, Blondeau K, Burdeska A, Ngwa I, Klingelschmitt G, Triyatni M, Yamamura T. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025 Jul; 99:106444.
-
Kwak-Kim J, Maier CC, Villano CM, Bowman CJ, Brennan FR, Stanislaus D, Hillegas A, Krayer J, Prell RA, Papenfuss TL, Cauvin A, Gamse J, Dahlman A, Enright B, Leshin L, Rao GK, Helms W, Fuller CL, Yang X, Chen C, Mitchell-Ryan S. Assessing the impact and risk of immunomodulatory compounds on pregnancy. J Reprod Immunol. 2025 Jun; 169:104453.
-
Corboy JR, Fox RJ, Cutter G, Engebretson E, Miller A, Morgan C, Gustafson T, Goodman AD, Kannan M, Sriram S, Xia Z, Lynch S, Bowen J, Kister I. DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial. Mult Scler. 2025 Feb; 31(2):159-173.
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|